Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_4
1
25%
Ph phase_1
1
25%
Ph phase_3
2
50%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(2)

Detailed Status

Completed2
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

not_yet_recruiting125%
completed250%
recruiting125%

Recent Activity

1 active trials
Showing 4 of 4
not_yet_recruitingphase_4

Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse

NCT07369115
completedphase_1

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

NCT04779177
completedphase_3

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

NCT04959032
recruitingphase_3

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

NCT06482554

Clinical Trials (4)

Showing 4 of 4 trials
NCT07369115Phase 4

Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse

Not Yet Recruiting
NCT04779177Phase 1

Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder

Completed
NCT04959032Phase 3

Lumateperone for the Prevention of Relapse in Patients With Schizophrenia

Completed
NCT06482554Phase 3

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4